Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;131(5):306-310.
doi: 10.1111/bcpt.13768. Epub 2022 Jul 16.

Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A population-based interrupted time series analysis

Jan D Kampmann  1   2 , Mads Nybo  3 , Frans Brandt  1   2 , Henrik Støvring  4   5 , Per Damkier  6   7 , Daniel P Henriksen  6   7 , Lars C Lund  5
Affiliations

Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A population-based interrupted time series analysis

Jan D Kampmann et al. Basic Clin Pharmacol Toxicol. 2022 Nov.

Abstract

In November 2013, the Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease was published, recommending statins for all individuals 50 years or older with an estimated glomerular filtration rate below 60 ml/min/1.73 m2 to lower the risk of major cardiovascular events. We quantified the prevalence of statin use among the target population before and after the guideline publication in a large Danish cohort of individuals with an estimated glomerular filtration rate below 60 ml/min/1.73 m2 , to investigate the effect of the guideline, but found no difference in the prevalence of statin use prior to and after the guideline publication.

Keywords: chronic kidney disease; guidelines; statins.

PubMed Disclaimer

Conflict of interest statement

JDK has no conflicts of interest to declare. MN has no conflicts of interest to declare. FB has no conflicts of interest to declare. HS reports personal fees from Bristol‐Myers‐Squibb, personal fees from Novartis and personal fees from Roche, outside the submitted work. He has personally received fees from Atrium education, the Danish Pharmaceutical Industry Association, for teaching a pharmacoepidemiology course. PD has no conflicts of interest to declare. DH has no conflicts of interest to declare. LCL reports participation in research projects funded by Menarini Pharmaceuticals and LEO Pharma with funds paid to the institution where he was employed.

Figures

FIGURE 1
FIGURE 1
The 90‐day period prevalence of statin use during the study period.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Matsushita K, Sang Y, Ballew SH, et al. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014;34(8):1770‐1777. - PMC - PubMed
    1. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet. 2011;377(9784):2181‐2192. - PMC - PubMed
    1. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238‐248. - PubMed
    1. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395‐1407. - PubMed
    1. Tonelli M, Wanner C. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group M. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014;160(3):182. - PubMed

MeSH terms

Substances